# Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

> **NCT01750073** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Nebraska** · enrollment: 92 (actual)

## Conditions studied

- Estrogen Receptor Negative
- Estrogen Receptor Positive
- HER2/Neu Negative
- HER2/Neu Positive
- Invasive Breast Carcinoma
- Progesterone Receptor Negative
- Progesterone Receptor Positive
- Stage IA Breast Cancer
- Stage II Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage III Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Therapeutic Conventional Surgery
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT01750073
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-12-07
- **Primary completion:** 2022-05-01
- **Final completion:** 2026-06
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01750073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01750073, "Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01750073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*